X4 Pharmaceuticals, Inc.

Pharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Trump Appointee Ferguson Keeps Biden-E

The European Medicines Agency has begun reviewing for potential pan-EU marketing approval 10 new products, including depemokimab, GSK’s IL-5 inhibitor that could become the first ultra-long-acting dru

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut